Oruka Therapeutics (0H79) Stock Statistics & Valuation Metrics
Total Valuation
Oruka Therapeutics has a market cap or net worth of $6.41B. The enterprise value is $5.12B.
- Market Cap
- $6.41B
- Enterprise Value
- $5.12B
Share Statistics
Oruka Therapeutics has 66,209,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 66,209,700
- Owned by Insiders
- 7.67%
- Owned by Institutions
- 0.32%
Financial Efficiency
Oruka Therapeutics’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -25.76%.
- Return on Equity (ROE)
- -0.22
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -25.76%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.55M
- Employee Count
- 68
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Oruka Therapeutics is -39.22. Oruka Therapeutics’s PEG ratio is -0.72.
- PE Ratio
- -39.22
- PS Ratio
- 0.00
- PB Ratio
- 5.46
- Price to FCF
- -63.41
- Price to Operating Cash Flow
- -60.35
- PEG Ratio
- -0.72
Income Statement
In the last 12 months, Oruka Therapeutics had revenue of 0 and earned -105.43M in profits. Earnings per share was -2.31.
- Revenue
- 0
- Gross Profit
- -83.00K
- Operating Income
- -122.05M
- Pretax Income
- -105.43M
- Net Income
- -105.43M
- EBITDA
- -105.35M
- Earnings Per Share (EPS)
- -2.31
Cash Flow
In the last 12 months, operating cash flow was -100.92M and capital expenditures -235,000, giving a free cash flow of -101.15M billion.
- Operating Cash Flow
- -100.92M
- Free Cash Flow
- -101.15M
- Free Cash Flow per Share
- -1.61
Dividends & Yields
Oruka Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.58%
- Earnings Yield
- -2.18%
Important Dates
Oruka Therapeutics upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Oruka Therapeutics as a current ratio of 22.37, with Debt / Equity ratio of 0.41%
- Current Ratio
- 22.37
- Quick Ratio
- 22.37
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.43
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Oruka Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Oruka Therapeutics EV to EBITDA ratio is -43.40, with an EV/FCF ratio of -60.78.
- EV to Sales
- 0.00
- EV to EBITDA
- -43.40
- EV to Free Cash Flow
- -60.78
- EV to Operating Cash Flow
- -60.92
Balance Sheet
Oruka Therapeutics has $873.56M in cash and marketable securities with $2.55M in debt, giving a net cash position of $871.02M billion.
- Cash & Marketable Securities
- $873.56M
- Total Debt
- $2.55M
- Net Cash
- $871.02M
- Net Cash Per Share
- $13.16
- Tangible Book Value Per Share
- $17.73
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Oruka Therapeutics is $151.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $151.90
- Price Target Upside
- ―
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 32.27%
Scores
- Smart Score
- 9
- AI Score
- ―